Human papillomavirus (HPV) is a viral pathogens. It is a different than Herpes Simplex Virus (HSV) and Human Immunodeficiency Virus (HIV). HPV is a major cause of throat, mouth, anus, penis, vagina, vulva, and cervical cancer. Various strains of HPV plays an important role in causing most cervical cancer. Cytomegalovirus (CMV) is also a viral pathogens and is the most common herpesvirus infection. It can spread through both sexual and non-sexual contact with body fluids, such as urine, breast milk, semen, and saliva. Symptoms may include fatigue, diarrhea, fever, hepatitis, pneumonia, shortness of breath, and gastrointestinal ulceration.
Growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market is mainly driven by the increasing number of sexually transmitted infections. According to World Health Organization’s (WHO) 2019 report, each year, more than 290 million women suffer from HPV infection worldwide, and every day, more than one million people suffer from sexually transmitted infections (STIs) worldwide. Thus, with increasing number of STIs, the demand for HPV and CMV therapeutics is also increasing, which, in turn, driving the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market growth.
Read More: https://coherentmarketorientedblogs.blogspot.com/2021/07/human-papillomavirus-hpv-and.html
